Clinical characteristics of severe influenza virus-associated pneumonia complicated with bacterial infection in children: a retrospective analysis

Background We aimed to investigate the clinical characteristics of severe influenza virus-associated pneumonia complicated with bacterial infection in children.

Methods We retrospectively analysed data concerning 64 paediatric patients with severe influenza virus-associated pneumonia who had been treated at our hospital.

The patients were divided into observation (44 patients) and control (20 patients) groups, based on the presence or absence of concomitant bacterial infection, and clinical data were compared between the groups.

Results The mean age in the observation group was 2.71 ± 1.44 years, 42 (95.45%) were aged ≤ 5 years, and 18 (40.9%) had underlying diseases.

The mean age in the control group was 4.05 ± 2.21 years, 13 (65%) were aged ≤ 5 years, and 3 (15%) had underlying diseases.

There was a statistically significant difference in patient age and the proportion of patients with underlying diseases ( P  < 0.05).

The observation group had higher duration of fever values, a higher number of patients with duration of fever ≥ 7 days, a higher incidence of gasping, and a higher incidence of seizures/consciousness disturbance, and the differences were statistically significant ( P  < 0.05).

Secondary bacterial infections in the observation group were mainly due to gram-negative bacteria, with Haemophilus influenzae and Moraxella catarrhalis being the most common pathogens.

The observation group had a higher proportion of patients treated in the paediatric intensive care unit and a longer hospital stay, and the differences were statistically significant ( P  < 0.05).

Conclusion Severe influenza virus-associated pneumonia complicated with bacterial infection was more common in children aged ≤ 5 years.

Younger patients with underlying diseases were more susceptible to bacterial infection (mainly due to gram-negative bacteria).

The timely administration of neuraminidase inhibitors and antibiotics against susceptible bacteria is likely to help improve cure rates.